<p>Arvinas, Inc.（纳斯达克代码：ARVN - 获取免费报告）首席会计官 David Loomis 于 5 月 11 日星期一出售了 1,919 股公司股票，交易总额为 19,074.86 美元，平均售价为 9.94 美元。交易完成后，首席会计官直接持有公司 40,193 股股票，价值约为 399,518.42 美元。这代表其持股减少了 4.56%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。</p>
<h2>Arvinas 价格表现</h2>
<ul>
<li>2023 年可能实现大幅增长的 3 只小型生物制药股票</li>
</ul>
<p>在周三的午盘交易中，ARVN 股票上涨了 0.30 美元，达到了 9.87 美元。该公司的交易量为 787,117 股，而其平均交易量为 855,453 股。Arvinas, Inc.的 1 年最低价为 5.90 美元，1 年最高价为 14.51 美元。该公司的市值为 6.3681 亿美元，市盈率为-7.71，贝塔值为 1.79。该公司的 50 日移动平均价格为 11.21 美元，200 日移动平均价格为 11.68 美元。</p>
<p>Arvinas（纳斯达克代码：ARVN - 获取免费报告）于 5 月 12 日星期二发布了季度财报。公司报告本季度每股收益（EPS）为-0.90 美元，超出分析师一致预期的-0.95 美元，超出幅度为 0.05 美元。Arvinas 的净利润率为-30.77%，股本回报率为-14.25%。本季度公司收入为 1560 万美元，而分析师预期为 1661 万美元。去年同期，公司每股收益为 1.14 美元。与去年同期相比，公司的季度收入下降了 91.7%。分析师平均预测 Arvinas, Inc.今年将发布-3.25 的每股收益。</p>
<h2>分析师设定新目标价</h2>
<p>ARVN 成为多份研究报告的主题。Wedbush 将 Arvinas 的目标价从 9.00 美元上调至 11.00 美元，并在 2 月 24 日的研究报告中给予公司 “中性” 评级。花旗集团将 Arvinas 的目标价从 21.00 美元上调至 24.00 美元，并在 5 月 4 日的研究报告中给予公司 “买入” 评级。巴克莱将 Arvinas 的目标价从 18.00 美元上调至 20.00 美元，并在周三的研究报告中给予公司 “增持” 评级。Weiss Ratings 在 4 月 10 日的研究报告中重申了对 Arvinas 的 “卖出（d-）” 评级。最后，Zacks Research 在 4 月 27 日的研究报告中将 Arvinas 的评级从 “持有” 下调至 “强烈卖出”。九位研究分析师对该股票给予了买入评级，三位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 15.14 美元。</p>
<p><strong>查看我们最新的 Arvinas 股票报告</strong></p>
<h2>Arvinas 的关键新闻</h2>
<p>以下是本周影响 Arvinas 的关键新闻：</p>
<ul>
<li>积极情绪：BTIG Research 将 Arvinas 的目标价从 16 美元上调至 18 美元，并重申买入评级，暗示当前水平有显著上行空间。BTIG 提高 Arvinas 目标价</li>
<li>积极情绪：Arvinas 与辉瑞达成了与 Rigel Pharmaceuticals 的许可协议，获得 VEPPANU（vepdegestrant）的全球独占权，前期支付 8500 万美元，过渡付款加上最多 3.2 亿美元的额外里程碑和特许权使用费。Arvinas 与辉瑞达成与 Rigel 的交易</li>
<li>积极情绪：公司表示 VEPPANU 成为首个获得 FDA 批准的 PROTAC，这验证了 Arvinas 的药物降解平台，并支持其产品管线故事。Arvinas 2026 年第一季度业绩和公司更新</li>
<li>中性情绪：第一季度业绩喜忧参半：Arvinas 报告每股损失小于预期的 0.90 美元，但收入为 1560 万美元未达预期，且较去年大幅下降。Arvinas 第一季度财报</li>
<li>中性情绪：投资者也在关注财报前的评论和会议记录，但这些内容似乎更多是信息性，而非市场驱动。Arvinas 财报电话会议记录</li>
<li>消极情绪：尽管产品和许可进展顺利，Arvinas 仍处于亏损状态，收入趋势疲软，这可能会抑制市场对该股票长期基本面的热情。Arvinas 盈利预期</li>
</ul>
<h2>机构投资者对 Arvinas 的看法</h2>
<p>几家机构投资者最近增加或减少了对公司的持股。ProShare Advisors LLC 在第四季度将其在 Arvinas 的持股增加了 7.2%。ProShare Advisors LLC 目前持有 14,827 股公司股票，价值 176,000 美元，此前在该期间内又购买了 993 股。Intech Investment Management LLC 在第三季度将其在 Arvinas 的持股增加了 3.6%。Intech Investment Management LLC 目前持有 32,653 股公司股票，价值 278,000 美元，此前在该期间内又购买了 1,125 股。MetLife Investment Management LLC 在第四季度将其在 Arvinas 的持股增加了 4.3%。MetLife Investment Management LLC 目前持有 33,810 股公司股票，价值 401,000 美元，此前在该期间内又购买了 1,381 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Arvinas 的持股增加了 5.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 38,636 股公司股票，价值 271,000 美元，此前在该期间内又购买了 2,122 股。最后，Oxford Asset Management LLP 在第二季度将其在 Arvinas 的持股增加了 15.5%。Oxford Asset Management LLP 目前持有 16,705 股公司股票，价值 123,000 美元，此前在该期间内又购买了 2,242 股。对冲基金和其他机构投资者持有公司 95.19% 的股票。</p>
<h2>关于 Arvinas</h2>
<p>（获取免费报告）</p>
<p>Arvinas, Inc NASDAQ: ARVN 是一家生物制药公司，专注于基于靶向蛋白降解的疗法开发。利用其专有的蛋白水解靶向嵌合体（PROTAC®）平台，Arvinas 旨在选择性地消除致病蛋白，而不仅仅是抑制其活性。这种新颖的方法有潜力解决一系列疾病，包括肿瘤学、神经退行性疾病和炎症，利用身体自然的蛋白质回收系统。</p>
<p>该公司的最先进临床候选药物针对激素驱动的癌症。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Arvinas</li>
<li>D-Wave 的财报看起来疲软，但投资者可能错过了这一点</li>
<li>随着人工智能反馈循环的加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
<li>Plug Power 开启盈利之路</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Arvinas 吗？</h2>
<p>在考虑 Arvinas 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Arvinas 并不在名单上。</p>
<p>虽然 Arvinas 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ARVN

辉瑞

<p>Arvinas, Inc.（纳斯达克代码：ARVN）首席会计官 David Loomis 以每股 9.94 美元的价格出售了 1,919 股，总计 19,074.86 美元，以支付股权奖励的税务义务。出售后，他持有 40,193 股，估值约为 399,518.42 美元，持股比例下降了 4.56%。该交易已向美国证券交易委员会（SEC）披露。Arvinas 报告第一季度每股亏损 0.90 美元，收入为 1560 万美元，未达到预期。分析师对该股票的评级不一，平均目标价为 15.14 美元。最近的进展包括与辉瑞的许可协议以及 BTIG 将目标价上调至 18 美元</p>

<p>Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CAO David Loomis sold 1,919 shares of the business's stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $19,074.86. Following the completion of the transaction, the chief accounting officer directly owned 40,193 shares of the company's stock, valued at approximately $399,518.42. This represents a 4.56% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p>
<div class="lb-trans"><p>Arvinas, Inc.（纳斯达克代码：ARVN - 获取免费报告）首席会计官 David Loomis 于 5 月 11 日星期一出售了 1,919 股公司股票，交易总额为 19,074.86 美元，平均售价为 9.94 美元。交易完成后，首席会计官直接持有公司 40,193 股股票，价值约为 399,518.42 美元。这代表其持股减少了 4.56%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。此次出售是为了覆盖与股权奖励归属相关的税款扣缴义务。</p>
</div><h2>Arvinas Price Performance</h2>
<div class="lb-trans"><h2>Arvinas 价格表现</h2>
</div><ul>
<li>3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023</li>
</ul>
<div class="lb-trans"><ul>
<li>2023 年可能实现大幅增长的 3 只小型生物制药股票</li>
</ul>
</div><p>ARVN stock traded up $0.30 during midday trading on Wednesday, reaching $9.87. The company had a trading volume of 787,117 shares, compared to its average volume of 855,453. Arvinas, Inc. has a 1 year low of $5.90 and a 1 year high of $14.51. The company has a market capitalization of $636.81 million, a P/E ratio of -7.71 and a beta of 1.79. The firm has a 50-day moving average price of $11.21 and a 200-day moving average price of $11.68.</p>
<div class="lb-trans"><p>在周三的午盘交易中，ARVN 股票上涨了 0.30 美元，达到了 9.87 美元。该公司的交易量为 787,117 股，而其平均交易量为 855,453 股。Arvinas, Inc.的 1 年最低价为 5.90 美元，1 年最高价为 14.51 美元。该公司的市值为 6.3681 亿美元，市盈率为-7.71，贝塔值为 1.79。该公司的 50 日移动平均价格为 11.21 美元，200 日移动平均价格为 11.68 美元。</p>
</div><p>Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.05. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business had revenue of $15.60 million during the quarter, compared to analysts' expectations of $16.61 million. During the same quarter in the previous year, the company earned $1.14 EPS. The business's quarterly revenue was down 91.7% compared to the same quarter last year. On average, equities analysts predict that Arvinas, Inc. will post -3.25 EPS for the current year.</p>
<div class="lb-trans"><p>Arvinas（纳斯达克代码：ARVN - 获取免费报告）于 5 月 12 日星期二发布了季度财报。公司报告本季度每股收益（EPS）为-0.90 美元，超出分析师一致预期的-0.95 美元，超出幅度为 0.05 美元。Arvinas 的净利润率为-30.77%，股本回报率为-14.25%。本季度公司收入为 1560 万美元，而分析师预期为 1661 万美元。去年同期，公司每股收益为 1.14 美元。与去年同期相比，公司的季度收入下降了 91.7%。分析师平均预测 Arvinas, Inc.今年将发布-3.25 的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>ARVN has been the subject of a number of research reports. Wedbush upped their price objective on shares of Arvinas from $9.00 to $11.00 and gave the company a &#34;neutral&#34; rating in a research note on Tuesday, February 24th. Citigroup upped their price objective on shares of Arvinas from $21.00 to $24.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, May 4th. Barclays upped their price objective on shares of Arvinas from $18.00 to $20.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Arvinas in a research note on Friday, April 10th. Finally, Zacks Research cut shares of Arvinas from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, April 27th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average price target of $15.14.</p>
<div class="lb-trans"><p>ARVN 成为多份研究报告的主题。Wedbush 将 Arvinas 的目标价从 9.00 美元上调至 11.00 美元，并在 2 月 24 日的研究报告中给予公司 “中性” 评级。花旗集团将 Arvinas 的目标价从 21.00 美元上调至 24.00 美元，并在 5 月 4 日的研究报告中给予公司 “买入” 评级。巴克莱将 Arvinas 的目标价从 18.00 美元上调至 20.00 美元，并在周三的研究报告中给予公司 “增持” 评级。Weiss Ratings 在 4 月 10 日的研究报告中重申了对 Arvinas 的 “卖出（d-）” 评级。最后，Zacks Research 在 4 月 27 日的研究报告中将 Arvinas 的评级从 “持有” 下调至 “强烈卖出”。九位研究分析师对该股票给予了买入评级，三位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “持有”，平均目标价为 15.14 美元。</p>
</div><p><strong>View Our Latest Stock Report on Arvinas</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Arvinas 股票报告</strong></p>
</div><h2>Key Arvinas News</h2>
<div class="lb-trans"><h2>Arvinas 的关键新闻</h2>
</div><p>Here are the key news stories impacting Arvinas this week:</p>
<div class="lb-trans"><p>以下是本周影响 Arvinas 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, suggesting meaningful upside from current levels. BTIG raises Arvinas price target</li>
<li>Positive Sentiment: Arvinas and Pfizer struck a licensing deal with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), bringing in $85 million upfront and transition payments plus up to $320 million in additional milestones and royalties. Arvinas and Pfizer deal with Rigel</li>
<li>Positive Sentiment: The company said VEPPANU became the first FDA-approved PROTAC, which validates Arvinas’ drug-degradation platform and supports its pipeline story. Arvinas Q1 2026 results and corporate update</li>
<li>Neutral Sentiment: First-quarter results were mixed: Arvinas reported a smaller-than-expected loss of $0.90 per share, but revenue of $15.6 million missed estimates and fell sharply from a year ago. Arvinas Q1 earnings report</li>
<li>Neutral Sentiment: Investors are also watching pre-earnings commentary and transcript coverage, but these items appear more informational than market-moving on their own. Arvinas earnings call transcript</li>
<li>Negative Sentiment: Despite the product and licensing progress, Arvinas remains unprofitable with weak revenue trends, which may temper enthusiasm for the stock’s longer-term fundamentals. Arvinas earnings expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：BTIG Research 将 Arvinas 的目标价从 16 美元上调至 18 美元，并重申买入评级，暗示当前水平有显著上行空间。BTIG 提高 Arvinas 目标价</li>
<li>积极情绪：Arvinas 与辉瑞达成了与 Rigel Pharmaceuticals 的许可协议，获得 VEPPANU（vepdegestrant）的全球独占权，前期支付 8500 万美元，过渡付款加上最多 3.2 亿美元的额外里程碑和特许权使用费。Arvinas 与辉瑞达成与 Rigel 的交易</li>
<li>积极情绪：公司表示 VEPPANU 成为首个获得 FDA 批准的 PROTAC，这验证了 Arvinas 的药物降解平台，并支持其产品管线故事。Arvinas 2026 年第一季度业绩和公司更新</li>
<li>中性情绪：第一季度业绩喜忧参半：Arvinas 报告每股损失小于预期的 0.90 美元，但收入为 1560 万美元未达预期，且较去年大幅下降。Arvinas 第一季度财报</li>
<li>中性情绪：投资者也在关注财报前的评论和会议记录，但这些内容似乎更多是信息性，而非市场驱动。Arvinas 财报电话会议记录</li>
<li>消极情绪：尽管产品和许可进展顺利，Arvinas 仍处于亏损状态，收入趋势疲软，这可能会抑制市场对该股票长期基本面的热情。Arvinas 盈利预期</li>
</ul>
</div><h2>Institutional Investors Weigh In On Arvinas</h2>
<div class="lb-trans"><h2>机构投资者对 Arvinas 的看法</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC boosted its position in Arvinas by 7.2% during the 4th quarter. ProShare Advisors LLC now owns 14,827 shares of the company's stock valued at $176,000 after buying an additional 993 shares during the period. Intech Investment Management LLC boosted its position in Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company's stock valued at $278,000 after buying an additional 1,125 shares during the period. MetLife Investment Management LLC boosted its position in Arvinas by 4.3% during the 4th quarter. MetLife Investment Management LLC now owns 33,810 shares of the company's stock valued at $401,000 after buying an additional 1,381 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock valued at $271,000 after buying an additional 2,122 shares during the period. Finally, Oxford Asset Management LLP boosted its position in Arvinas by 15.5% during the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company's stock valued at $123,000 after buying an additional 2,242 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了对公司的持股。ProShare Advisors LLC 在第四季度将其在 Arvinas 的持股增加了 7.2%。ProShare Advisors LLC 目前持有 14,827 股公司股票，价值 176,000 美元，此前在该期间内又购买了 993 股。Intech Investment Management LLC 在第三季度将其在 Arvinas 的持股增加了 3.6%。Intech Investment Management LLC 目前持有 32,653 股公司股票，价值 278,000 美元，此前在该期间内又购买了 1,125 股。MetLife Investment Management LLC 在第四季度将其在 Arvinas 的持股增加了 4.3%。MetLife Investment Management LLC 目前持有 33,810 股公司股票，价值 401,000 美元，此前在该期间内又购买了 1,381 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Arvinas 的持股增加了 5.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 38,636 股公司股票，价值 271,000 美元，此前在该期间内又购买了 2,122 股。最后，Oxford Asset Management LLP 在第二季度将其在 Arvinas 的持股增加了 15.5%。Oxford Asset Management LLP 目前持有 16,705 股公司股票，价值 123,000 美元，此前在该期间内又购买了 2,242 股。对冲基金和其他机构投资者持有公司 95.19% 的股票。</p>
</div><h2>About Arvinas</h2>
<div class="lb-trans"><h2>关于 Arvinas</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.</p>
<div class="lb-trans"><p>Arvinas, Inc NASDAQ: ARVN 是一家生物制药公司，专注于基于靶向蛋白降解的疗法开发。利用其专有的蛋白水解靶向嵌合体（PROTAC®）平台，Arvinas 旨在选择性地消除致病蛋白，而不仅仅是抑制其活性。这种新颖的方法有潜力解决一系列疾病，包括肿瘤学、神经退行性疾病和炎症，利用身体自然的蛋白质回收系统。</p>
</div><p>The company's most advanced clinical candidates address hormone-driven cancers.</p>
<div class="lb-trans"><p>该公司的最先进临床候选药物针对激素驱动的癌症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Arvinas</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
<li>Plug Power Flips The Switch On Profitability</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Arvinas</li>
<li>D-Wave 的财报看起来疲软，但投资者可能错过了这一点</li>
<li>随着人工智能反馈循环的加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
<li>Plug Power 开启盈利之路</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arvinas Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Arvinas 吗？</h2>
</div><p>Before you consider Arvinas, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arvinas 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Arvinas 并不在名单上。</p>
</div><p>While Arvinas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arvinas 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock

- Arvinas, Inc. CAO David Loomis 于 5 月 11 日出售 1,919 股股票，总成交额 $19,074.86。  
- 此次交易后，其持股数减少 4.56%，现拥有 40,193 股，价值约 $399,518.42。  
- 公司第一季度营收 $15.60 百万，同比下降 91.7%。

内幕交易：Arvinas（NASDAQ:ARVN）的首席会计官出售了 1,919 股股票